The Interreg NWE project Codex4SMEs is proud to organise this interactive online seminar with Hans Peter Mulder addressing the topic: If liquid biopsies are 100% efficient, they would still yield only a handful of cancer cells per blood sample. How reliable can a diagnostic test be when you’re limited to a handful of cancer cells? Idris Oncology is developing a technology that will yield hundreds of cancer cells per patient by not taking a blood sample, but by sampling in the blood.
- 14:30 – 14:35 – Words of welcome and short Codex4SMEs project introduction
- 14:35 – 14:50 – Idris Oncology: In vivo enrichment of circulating tumor cells
by Hans Peter Mulder, CEO and founder of Idris Oncology
- 14:50 – 15:30 – Discussion round – Moderator Lonneke Baas
- Hans Peter Mulder
CEO and founder of Idris Oncology in Leiden, The Netherlands
Hans Peter Mulder graduated cum laude in Molecular Biology at Leiden University. During his studies he focused on neurophysiology and circadian biology. Despite these highly biology oriented disciplines, he has always maintained an unusual fascination for the technological and engineering aspects. This ultimately resulted in the firm belief that biology and technology should be combined more often, to solve old problems and to create entirely unforeseen opportunities.